Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.
Anticentromere antibodies (ACA) and anti-topoisomerase I (anti-topo I) were assayed in serum samples from 355 patients: 89 with proximal scleroderma; 54 with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), without proximal scleroderma; 154 with primary and secondary Raynaud's disease; and 58 with other rheumatic diseases, without Raynaud's disease. Sera from healthy control subjects were also assayed. Using immunoblotting techniques, anti-topo I was detected in 28% of the patients with proximal scleroderma; using immunodiffusion techniques, this antibody was found in only 20% of the same group of patients. Anti-topo I and ACA were found primarily in patients with scleroderma, CREST syndrome, and Raynaud's phenomenon. ACA identified patients with less severe disease, whereas anti-topo I identified patients with skin and cardiac involvement and patients with malignancies.
Weiner
E S
ES
Department of Medicine, University of Connecticut School of Medicine, Farmington 06032.
Earnshaw
W C
WC
Senécal
J L
JL
Bordwell
B
B
Johnson
P
P
Rothfield
N F
NF
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D002503:Centromere / Q000276:immunology*; D002875:Chromosomes / Q000276:immunology*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D003710:Demography; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000276:immunology; D012216:Rheumatic Diseases / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D012595:Scleroderma, Systemic / Q000276:immunology*; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology; D013577:Syndrome
D000906:Antibodies; D004264:DNA Topoisomerases, Type I